Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01447576 · ClinicalTrials.gov registry record · Phase 2
Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,036
- Enrollment target
NCT01447576 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 1,036 participants.
The verdict
NCT01447576, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,036 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as adjunctive therapy in the treatment of adult patients with Major Depressive Disorder (MDD).
Interventions
- DRUG ADT
- DRUG OPC-34712
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,036 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01447576
The ClinicalTrials.gov registry entry for NCT01447576 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,036 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ADT is the first listed.
NCT01447576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01447576 about?
NCT01447576 is a clinical study titled "Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder". The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as adjunctive therapy in the treatment of adult patients with Major Depressive Disorder (MDD).
What is the current status of trial NCT01447576?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,036 participants. The study started on 2009-09. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01447576?
The interventions under investigation include: ADT (DRUG), OPC-34712 (DRUG).
Who is sponsoring clinical trial NCT01447576?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.